Cidara Therapeutics Obtains $32,000,000 Series A Financing Round

  • Feed Type
  • Date
    6/30/2014
  • Company Name
    Cidara Therapeutics
  • Mailing Address
    6310 Nancy Ridge Drive San Diego, CA 92121 USA
  • Company Description
    Our vision is to apply the versatile Cloudbreak small molecule immunotherapy platform to treat patients with compromised immune systems across multiple therapeutic areas. We will initially target patients with compromised immune systems resulting from cancer therapy, bone marrow transplants and solid organ transplants where the risk of death from invasive fungal infections, even on best available care, often exceeds 50 percent. Our objective is to rewrite the book on how such infections are treated.
  • Website
    Undisclosed
  • Transaction Type
    Venture Equity
  • Transaction Amount
    $32,000,000
  • Transaction Round
    Series A
  • Proceeds Purposes
    The funding will enable it to advance candidates from the company’s Cloudbreak targeted immunotherapy platform and biafungin, a novel long acting echinocandin antifungal drug, into human clinical studies.
  • M&A Terms
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor
  • Venture Investor